Skip to content
n:ews

Tag: Bambusa

Health Corporate action

Dermatology Biotech Bambusa Slides After $168.9 Million IPO

Bambusa Therapeutics raised $168.9 million in an upsized US initial public offering, pricing 10.6 million shares at $16, the midpoint of its range. The stock opened at $14.88, about 7% below the offer price, for a market value near $758 million. The Nasdaq-listed company develops bispecific antibodies for immunology and inflammation, led by a candidate for atopic dermatitis.